ClinicalTrials.Veeva

Menu
IMA Clinical Research | Albuquerque Neuroscience logo

IMA Clinical Research | Albuquerque Neuroscience

Research site

Site insights

Top conditions

Top treatments

Rimegepant
Orforglipron
Agomelatine
BI 456906
Flibanserin
TRx0237
LY3502970
Troriluzole
Iloperidone
Tirzepatide

Parent organization

This site is a part of IMA Clinical Research

Data sourced from clinicaltrials.gov

Contact this site

IMA Clinical Research- Albuquerque

Verified by this site

Active trials

14 of 29 total trials

A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling
Alzheimer Disease
Drug: Donanemab
Drug: Placebo

The main purpose of this study is to determine safety and efficacy of orforglipron compared with insulin glargine in participants with type 2 diabete...

Enrolling
Chronic Kidney Disease
Overweight
Drug: Orforglipron
Drug: Insulin Glargine

The purpose of this study is to evaluate the safety, reactogenicity, and relative vaccine efficacy (rVE) of the mRNA-1283.222 vaccine as well as its...

Active, not recruiting
COVID-19
Biological: mRNA-1273.222
Biological: mRNA-1283.222

This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult part...

Active, not recruiting
Overweight
Obesity
Drug: Orforglipron
Drug: Placebo

This is a Phase 2B clinical study evaluating the effectiveness and safety of SP-624 as compared to placebo in the treatment of adults with Major Depr...

Enrolling
Major Depressive Disorder
Drug: SP-624
Drug: Placebo

This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additiona...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: Tirzepatide

The primary purpose of this study is to evaluate the efficacy of ACU193 infusions administered once every four weeks (Q4W) in slowing cognitive and f...

Enrolling
Alzheimer Disease
Drug: ACU193
Drug: Placebo

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

The purpose of this clinical study is to learn about the safety, extent of the side effects (reaction to vaccine), and immune response (your immune s...

Enrolling
Shingles
Human
Biological: Selected Vaccine Candidate group (Dose level, Schedule)
Biological: Shingrix - SSB

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Enrolling
Obesity
Drug: Placebo
Drug: survodutide

The purpose of this study is to compare the efficacy and safety of rimegepant to placebo as a preventative treatment for migraine in children and ado...

Enrolling
Migraine
Drug: Placebo
Drug: Rimegepant

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling
Generalized Anxiety Disorder
Drug: Placebo
Drug: ENX-102

The objective of this study is to determine the safety and tolerability of fosgonimeton (ATH-1017) in subjects with mild to moderate Alzheimer's dise...

Active, not recruiting
Alzheimer Disease
Drug: ATH-1017

The purpose of this study is to determine efficacy differences between ALTO-100 and placebo, used either as monotherapy or adjunctively to an antidep...

Enrolling
Major Depressive Disorder
Drug: Placebo
Drug: ALTO-100

Trial sponsors

Lilly logo
Pfizer logo
V
Boehringer Ingelheim logo
Novartis logo
A
A
Alto Neuroscience logo
Athira Pharma logo
Biohaven logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems